Sort
82,697 grants matching “vaccine development”
Medical Scientist Training Program
$1,072,157Terence S. Dermody · Vanderbilt University · T32 · FY2010 · GM
Host and Viral Genetics Core
$1,072,115David B. Goldstein · Duke University · U19 · FY2008 · AI
Experimental characterization of the dynamics of immune responses to influenza
$1,072,039Rafi Ahmed · Emory University · U19 · FY2019 · AI
Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications
$1,071,960Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2006 · CA
ADOLESCENT MEDICINE TRIALS UNIT (AMTU)
$1,071,790Mount Sinai School Of Medicine Of Nyu · U01 · FY2003 · HD
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,071,736John Givens · Starks Associates, Inc. · N01 · FY2015 · AI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,071,699Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Project 3: Anti-HIV/SHIV Efficacy of Combination Antiretroviral Intravaginal Ring
$1,071,457Richard B Pyles · Oak Crest Institute Of Science · U19 · FY2017 · AI
Immunization against filamentous bacteriophages to prevent bacterial infection
$1,071,154Patrick R Secor · University Of Montana · R01 · FY2021 · AI
Large Scale T Cell Epitope Discovery for Burkholderia pseudomallei
$1,071,117Daniel Altmann · Imperial College Of Science, Technology And Medicine · N01 · FY2012 · AI
Natural History of HPV Infections in Mid-adult Women
$1,071,079Rachel L. Winer · University Of Washington · P01 · FY2010 · AI
HPV Disease in the Era of HPV Vaccines
$1,071,079Rachel L. Winer · University Of Washington · P01 · FY2010 · AI
Centralized HIV-1 Genes as Vaccines
$1,071,043Duke University · P01 · FY2005 · AI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee
$1,070,762Frank R. Jones · Etubics Corporation · R44 · FY2009 · AI
A Tetravalent Dengue Vaccine Based on Alphavirus Replicons
$1,070,488Laura J White · Global Vaccines, Inc. · U01 · FY2012 · AI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure
$1,070,482Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2024 · AI
Laboratory And Preclinical Studies Of Flaviviruses
$1,070,401Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Novel Sensor Integrated Proteome on Chip (SPOC) platform for evaluating kinetic parameters of protein interactions in high throughput
$1,070,227Bharath Takulapalli · Spoc Proteomics Inc. · R44 · FY2023 · TR
Interaction of HIV envelope with cell surface receptors
$1,069,830Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis
$1,069,830Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Synthesize and Produce HIV-1 Envelope Glycopeptide Immunogen Nanoparticle Vaccine(s)
$1,069,648Thomas Vancott · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI
HIV-1 Reverse Transcriptase
$1,069,644Stephen H Hughes · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
A Novel Systemic and Mucosal Adjuvant for Biodefense
$1,069,641Robert E. Johnston · Global Vaccines, Inc. · U01 · FY2009 · AI
Profiling cancer neoantigen repertoires and validating immunotherapy targets
$1,069,555Martin W McIntosh · Fred Hutchinson Cancer Research Center · U01 · FY2015 · CA
A nanoparticle-based immunoprophylactic strategy that protects against a broad sp
$1,069,167Allen G Harmsen · Montana State University - Bozeman · R56 · FY2010 · AI